Phase 2 trial: Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia
26 Feb, 2021 | 08:30h | UTCMuscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Phase II Results Promising for New Schizophrenia Drug Combo – MedPage Today